ENSC.US Ensysce Biosciences Inc

Healthcare Biotechnology USA Stocks
0.4184 USD
Close of Nov 14, 2026
0.2300 2.16
Market cap
USD 8.14M
P/E
-
P/B
0.86x
ROE
-428.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ENSC.US undervalued?

Graham number

The Graham number of Ensysce Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ensysce Biosciences Inc fundamental analysis

No fundamental analysis for Ensysce Biosciences Inc yet.

Ensysce Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ensysce Biosciences Inc

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead…

Full company profile